- Home
- RMI vs GOSS Comparison
RMI vs GOSS Comparison
Compare RMI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMI | GOSS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 83.2M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMI | GOSS |
|---|---|---|
| Price | $14.83 | $0.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.19 |
| AVG Volume (30 Days) | 9.1K | ★ 15.0M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.22 | $0.11 |
| 52 Week High | $16.36 | $3.87 |
Technical Indicators
Market Signals| Indicator | RMI | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 45.97 |
| Support Level | $14.66 | $0.14 |
| Resistance Level | $15.51 | $0.20 |
| Average True Range (ATR) | 0.15 | 0.02 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 1.21 | 22.71 |
Price Performance
Historical ComparisonAbout RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).